Erik Gatenholm is Co-Founder and CEO here at CELLINK. In 2017, he founded CELLINK to revolutionize the way that we conduct medical research worldwide. He led a workshop at the C2 Montreal conference called “Need a tissue, Bioprinting is the next Medical Revolution”
At C2 Montreal – There was a presentation on bioprinting and Cellink technology.
Then there was an activity where people in groups looked at a sample of bioprinted tissue and people worked on exercises of what people thought was possible or preposterous in the future.
There was a forecast of increased tissue engineering enhanced plastic surgery.
There was then an exercise on considering the implications.
There would be a society where people looked more similar.
Both the forecast and the implication are already in an advanced state in South Korea.
South Korea has the highest per capita rate of cosmetic surgery in the world, by one key industry estimate. Gallup Korea found about one in three South Korean women between the ages of 19 and 29 said they’ve gone under the knife, though some counts put the number even higher. Most of the surgeries are eyelid procedures and the vast majority of plastic surgery patients are women.
South Korea has industrialized the ideal [beauty]. The ideal is being created by the beauty industry, by K-pop [Korean pop music], by perhaps even the government, in what they’re selling to the rest of the world as to the ideal Korean beauty.
Every ad in the Seoul Metro’s Apujeong station is for a plastic surgery clinic. In response to a growing number of complaints from riders, the Seoul Metro announced it will ban advertisements for cosmetic surgery at its stations. However, the phase out will not be complete until about 2022. Elise Hu/NPR
Cellink focuses on the development and commercialization of bioprinting technologies that allow researchers to 3D print human organs and tissues for the development of pharmaceutical and cosmetic products, and in the future, for clinical applications. CELLINK’s innovative and patent pending bioink is a biomaterial innovation that enables human cells to grow and thrive such as they would in the natural human body environment. Today, the company’s disruptive technology platform is being utilized to print tissues such as liver, cartilage, skin, and even fully functional cancer tumors that can then be used to develop new cancer treatments. The company has, within 12 months, been able to commercialize products in more than 40 countries and sold to more than hundreds of prestigious labs around the world, such as Harvard, MIT, Princeton, and FDA.
BIO X is the new go-to 3d bioprinter for life science companies, researchers and innovators who work with bioprinting. Built to meet the needs of today’s bio-scientists, BIO X’s responsive Neocortex M1 internal computer coupled with HeartOS, the most powerful bioprinting operating system out there, allows the user to orchestrate the intricate process of building human tissues. BIO X is the most user friendly bioprinter on the market and a complete standalone product.